Navigation Links
VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine,Candidates Trigger Robust Immune Responses and Protection in,Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals' novel pandemic influenza vaccine candidates triggered protective immune responses in pre-clinical challenge studies, according to data presented for the first time today at the Third International Conference on DNA Vaccines in Malaga, Spain.

VGX scientists created four synthetic consensus DNA vaccines to protect against a lethal Vietnamese H5N1strain of avian influenza in mice. One of the vaccines resulted in complete protection of mice from death and illness of the challenge while 2 others had 60-80% protective effects. All of the vaccines were delivered using VGX's proprietary CELLECTRA(TM) DNA Delivery Device. CELLECTRA(TM) is a novel adaptive electroporation device developed by VGX. The avian flu data was presented by Dr. Ruxandra Draghia-Akli, VGX Vice President, Immune Therapeutics Research.

Separately at the opening plenary session, Professor David B. Weiner of the University of Pennsylvania, Conference Chairman and a Co-founder of VGX, presented new data showing extensive T-cell mediated immune responses to VGX's HIV vaccine candidates delivered with CELLECTRA(TM) in non-human primates. Most notably, the monkeys immunized with VGX vaccines displayed HIV-specific T cell responses as much as 10-20 fold greater than those reported in the literature using other vaccine modalities. Induction of high levels of T cell immune responses, especially the CD8+ Killer T cell responses, has long been thought to be important for developing a successful vaccine for HIV.

VGX plans to conduct further preclinical studies for both the HIV and Avian Flu vaccines, including the IND-enabling toxicology studies in 2007.

From the conference in Malaga, Spain, Dr. J. Joseph Kim, President and CEO of VGX, commented, "Our data demonstrates the potential of our DNA vaccine approaches in addressing these significant global health problems. We pla n to further collaborate with experts and leading organizations in the field in order to advance our promising clinical programs forward."

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecules and biologics product candidates for the treatment of infectious diseases, cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR(TM) for HIV infection and VGX-410C for chronic HCV infection, both of which are currently in Phase II clinical trials. In addition, Phase I clinical trials will be initiated in 2007 for VGX-150 for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX's research pipelines include new generation of DNA vaccines and therapeutics as well as CELLECTRA(TM), a proprietary DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Contact

VGX Pharmaceuticals
Kevin W. Rassas, 267-440-4208
Senior Vice President
Fax: 267-440-4242
Rassas@vgxp.com
www.vgxp.com


'"/>




Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):